gefitinib has been researched along with imiquimod in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (imiquimod) | Trials (imiquimod) | Recent Studies (post-2010) (imiquimod) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 3,264 | 284 | 1,963 |
| Protein | Taxonomy | gefitinib (IC50) | imiquimod (IC50) |
|---|---|---|---|
| Histamine H2 receptor | Homo sapiens (human) | 1.506 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 2.621 | |
| Adenosine receptor A2a | Homo sapiens (human) | 5.32 | |
| 7,8-dihydro-8-oxoguanine triphosphatase | Homo sapiens (human) | 0.646 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
1 review(s) available for gefitinib and imiquimod
| Article | Year |
|---|---|
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
1 other study(ies) available for gefitinib and imiquimod
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |